Boehringer walks away from Zealand's lead glucagon/GLP-1 receptor agonist
This article was originally published in Scrip
Boehringer Ingelheim and Zealand Pharma have had a difference of opinion over ZP2929, the lead compound in their development program for novel dual-acting glucagon/GLP-1 receptor agonists for diabetes and potentially obesity.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.